BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 9369495)

  • 1. Characterization of phosphine complexes of technetium(III) as transport substrates of the multidrug resistance P-glycoprotein and functional markers of P-glycoprotein at the blood-brain barrier.
    Luker GD; Rao VV; Crankshaw CL; Dahlheimer J; Piwnica-Worms D
    Biochemistry; 1997 Nov; 36(46):14218-27. PubMed ID: 9369495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel technetium (III)-Q complexes for functional imaging of multidrug resistance (MDR1) P-glycoprotein.
    Crankshaw CL; Marmion M; Luker GD; Rao V; Dahlheimer J; Burleigh BD; Webb E; Deutsch KF; Piwnica-Worms D
    J Nucl Med; 1998 Jan; 39(1):77-86. PubMed ID: 9443741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and BCRP/MXR/ABCP on the transport of (99m)Tc-tetrofosmin.
    Chen WS; Luker KE; Dahlheimer JL; Pica CM; Luker GD; Piwnica-Worms D
    Biochem Pharmacol; 2000 Aug; 60(3):413-26. PubMed ID: 10856437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a 67Ga/68Ga radiopharmaceutical for SPECT and PET of MDR1 P-glycoprotein transport activity in vivo: validation in multidrug-resistant tumors and at the blood-brain barrier.
    Sharma V; Prior JL; Belinsky MG; Kruh GD; Piwnica-Worms D
    J Nucl Med; 2005 Feb; 46(2):354-64. PubMed ID: 15695797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution.
    Shaik N; Giri N; Pan G; Elmquist WF
    Drug Metab Dispos; 2007 Nov; 35(11):2076-85. PubMed ID: 17709369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
    Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
    Chen Y; Agarwal S; Shaik NM; Chen C; Yang Z; Elmquist WF
    J Pharmacol Exp Ther; 2009 Sep; 330(3):956-63. PubMed ID: 19491323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a novel 99mTc-carbonyl complex as a functional probe of MDR1 P-glycoprotein transport activity.
    Dyszlewski M; Blake HM; Dahlheimer JL; Pica CM; Piwnica-Worms D
    Mol Imaging; 2002; 1(1):24-35. PubMed ID: 12920858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results.
    Yamazaki M; Neway WE; Ohe T; Chen I; Rowe JF; Hochman JH; Chiba M; Lin JH
    J Pharmacol Exp Ther; 2001 Mar; 296(3):723-35. PubMed ID: 11181899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice.
    Zhou L; Schmidt K; Nelson FR; Zelesky V; Troutman MD; Feng B
    Drug Metab Dispos; 2009 May; 37(5):946-55. PubMed ID: 19225039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain penetration of ivermectin and selamectin in mdr1a,b P-glycoprotein- and bcrp- deficient knockout mice.
    Geyer J; Gavrilova O; Petzinger E
    J Vet Pharmacol Ther; 2009 Feb; 32(1):87-96. PubMed ID: 19161460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transport of phosphatidylcholine in MDR3-negative epithelial cell lines via drug-induced MDR1 P-glycoprotein.
    Abulrob AG; Gumbleton M
    Biochem Biophys Res Commun; 1999 Aug; 262(1):121-6. PubMed ID: 10448079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of P-glycoprotein in intestinal transport versus the BBB transport of tetraphenylphosphonium.
    Swed A; Eyal S; Madar I; Zohar-Kontante H; Weiss L; Hoffman A
    Mol Pharm; 2009; 6(6):1883-90. PubMed ID: 19722701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP.
    Germann UA; Ford PJ; Shlyakhter D; Mason VS; Harding MW
    Anticancer Drugs; 1997 Feb; 8(2):141-55. PubMed ID: 9073310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and characterization of LLC-PK1 cells containing Sprague-Dawley rat Abcb1a (Mdr1a): comparison of rat P-glycoprotein transport to human and mouse.
    Booth-Genthe CL; Louie SW; Carlini EJ; Li B; Leake BF; Eisenhandler R; Hochman JH; Mei Q; Kim RB; Rushmore TH; Yamazaki M
    J Pharmacol Toxicol Methods; 2006; 54(1):78-89. PubMed ID: 16545584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein.
    Lee YJ; Kusuhara H; Jonker JW; Schinkel AH; Sugiyama Y
    J Pharmacol Exp Ther; 2005 Jan; 312(1):44-52. PubMed ID: 15448171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP.
    Römermann K; Wanek T; Bankstahl M; Bankstahl JP; Fedrowitz M; Müller M; Löscher W; Kuntner C; Langer O
    Nucl Med Biol; 2013 Oct; 40(7):873-8. PubMed ID: 23845421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, molecular structure, and validation of metalloprobes for assessment of MDR1 P-glycoprotein-mediated functional transport.
    Sivapackiam J; Harpstrite SE; Prior JL; Gu H; Rath NP; Sharma V
    Dalton Trans; 2010 Jul; 39(25):5842-50. PubMed ID: 20505882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
    Tang SC; Nguyen LN; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Int J Cancer; 2014 Mar; 134(6):1484-94. PubMed ID: 24037730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sestamibi is a substrate for MDR1 and MDR2 P-glycoprotein genes.
    Joseph B; Bhargava KK; Malhi H; Schilsky ML; Jain D; Palestro CJ; Gupta S
    Eur J Nucl Med Mol Imaging; 2003 Jul; 30(7):1024-31. PubMed ID: 12536246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.